ATHAライブシグナル | Getagraph.comで利益を最大化

売る 108138 min ago

@ $3.22

発行日: 14 2月 2024 @ 23:30

リターン: -38.66%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: 1.26 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation...

Stats
本日の出来高	119 993
平均出来高	355 087
時価総額	75.70M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.800 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.640
ATR14	$0.00700 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	San Martin Javier	Buy	400 000	Stock Option (Right to Buy)
2024-04-15	San Martin Javier	Buy	0
2024-02-15	Litton Mark James	Buy	650 000	Stock Option (Right to Buy)
2024-02-14	Worthington Mark	Buy	220 000	Stock Option (Right to Buy)
2024-02-14	Church Kevin	Buy	220 000	Stock Option (Right to Buy)

INSIDER POWER
98.60
Last 99 transactions
Buy: 6 665 546 \| Sell: 65 252

ボリューム相関

長: 0.27 (neutral)

短: -0.40 (neutral)

Signal:(58.373) Neutral

Athira Pharma, Inc. 相関

10 最も正の相関
SGBX	0.898
VNET	0.893
SRTS	0.888
ABST	0.885
CNDT	0.883
RYTM	0.883
FREQ	0.882
INFI	0.876
FNWB	0.875
SBBP	0.874

10 最も負の相関
RDUS	-0.883
CRWD	-0.879
LVO	-0.878
TYHT	-0.877
PAE	-0.873
ZGNX	-0.873
ICON	-0.873
PETV	-0.869
MRNS	-0.859
RDI	-0.851

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Athira Pharma, Inc. 相関 - 通貨/商品

0.29
( neutral )

0.14
( neutral )

0.00
( neutral )

0.61
( weak )

0.16
( neutral )

Athira Pharma, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-969 000 (0.00 %)
EPS:	$-3.09

FY	2023
収益:	$0
総利益:	$-969 000 (0.00 %)
EPS:	$-3.09

FY	2022
収益:	$0
総利益:	$-1.05M (0.00 %)
EPS:	$-2.31

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-4.58

Financial Reports:

No articles found.

Athira Pharma, Inc.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.